Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Dermatologic 3Breast 3Gastrointestinal 2CNS 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1

Conditions

Melanoma 3

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × saponin QA-21V1 × Dermatologic × Clear all
NCT00003224 2014-11-20

Vaccine Therapy in Treating Patients With Metastatic Melanoma

University of Virginia

Phase 1 Completed
22 enrolled 14 charts
Dermatologic

Melanoma

NCT00003362 2013-06-25

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
Dermatologic

Melanoma

NCT00005052 2009-02-09

Vaccine Therapy in Treating Patients With Primary Stage II Melanoma

National Cancer Institute (NCI)

Phase 3 Unknown
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡